{
    "nct_id": "NCT05382299",
    "official_title": "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1",
    "inclusion_criteria": "* Individuals, regardless of race and ethnic group, with previously untreated locally advanced, inoperable or metastatic triple-negative breast cancer (TNBC)\n\n  * Individuals whose tumors are programmed cell death ligand 1 (PD-L1) negative at screening or individuals whose tumors are PD-L1 positive at screening if they have received an anti-PD-(L)1 inhibitor in the (neo) adjuvant setting or if they cannot be treated with a checkpoint inhibitor due to a comorbidity\n  * Centrally confirmed TNBC and PD-L1 status on fresh or archival tissue\n  * Individuals must have completed treatment for Stage I-III breast cancer, if indicated, and â‰¥ 6 months must have elapsed (with the exception of endocrine therapy) between completion of treatment with curative intent and first documented local or distant disease recurrence\n  * Individuals presenting with de novo metastatic TNBC are eligible\n* Measurable disease based on computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. as evaluated locally\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Demonstrates adequate organ function\n* Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception\n* Individuals with human immunodeficiency virus (HIV) must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Positive serum pregnancy test or women who are lactating\n* Received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment\n* Have not recovered from adverse events (AEs) due to a previously administered agent at the time study entry\n* May not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible\n* Previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor\n* Active second malignancy\n* Active serious infection requiring antibiotics\n* Positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}